Our present study revealed that CXCL1 concentrations were significantly higher in CRC patients when compared to healthy controls, and were similar to those of the classical tumor biomarker CEA and the marker of inflammation CRP. This evidence concerns the gene CEACAM5 and colorectal carcinoma.